Clinical trial
Dose Ranging Study Of Solabegron Versus Placebo In Female Patients With…
NCT00343486 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00343486 |
|---|---|
| Title | Dose Ranging Study Of Solabegron Versus Placebo In Female Patients With Overactive Bladder Symptoms |
| Official title | An Eight- Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group Proof of Concept Study to Assess the Efficacy, Safety and Tolerability as Well as the Pharmacokinetic Profile of Oral Solabegron (GW427353) 125mg and 50mg Administered Twice Daily vs Placebo in Women With Overactive Bladder |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Overactive Bladder |
| Intervention type | Drug |
| Interventions | Solabegron |
| Enrollment | 240 |
| Start date | May 1, 2006 |
| First posted | Jun 23, 2006 |
| Last update posted | May 18, 2009 |
| Countries | Argentina, Australia, Finland, France, Germany, Latvia, Netherlands, New Zealand, Poland, Slovenia, South Africa, South Korea and 2 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: